A nanovaccine with dual toll-like receptor agonists based on CaP mineralized PLGA nanoparticle for preventing HPV infections

Author:

Chi Yongjie1,Jia Chengcheng1,Zhong Weiting2,Yang Zhu1,Cheung Ocean3,Lu Yu4,Zhao Yanping2,Wang Hongjun2,Chen Jianping5,Wang Lianyan1

Affiliation:

1. Institute of Process Engineering

2. Beijing Tide Pharmaceutical Co., Ltd

3. Uppsala University

4. Jiangsu Academy of Agricultural Sciences

5. Beijing Health Guard Biotechnology Co., LTD

Abstract

Abstract In developing countries where females are threatened by HPV, reducing the costs of production and transport of HPV vaccine is still one of pressing issues that needs a sustainable solution. Although HPV vaccines currently in use with aluminum adjuvants demonstrate significant stimulation of humoral immunity, the weak cellular immune response they elicit indicates a need for further improvement. On the other hand, the issue of poor immune promotion effect of single use of toll-like receptor agonists also needs to be addressed. Here, a double Toll like receptor agonist (R848, Poly (I:C)) HPV vaccine, with HPV16 L1 pentamer as antigen, was fabricated by using calcium phosphate (CaP) mineralized PLGA nanoparticles. This reinforced vaccine shows better stimulation of both humoral and cellular immune responses than aluminum-adjuvanted vaccines when exposed to dual TLR agonists.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3